S1B-3006

**S1B-3006** is an investigational, non-hormonal fixed-dose combination being developed by S1 Biopharma for treatment-resistant sexual dysfunction, including low sexual desire and other sexual-function problems associated with general medical conditions. A 2014 S1 Biopharma SEC filing described it as a proprietary combination of the active components in Lorexys and S1B-307; Lorexys contains bupropion and trazodone, while S1B-307 was described as a peptide candidate for sexual arousal and orgasmic disorders with an undisclosed molecular target. S1 Biopharma's current pipeline identifies S1B-3006 as a follow-on program for treatment-resistant sexual dysfunction in men and women. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1613723/000104746914009025/a2222124zs-1a.htm))